Immunophotonics Announces Issuance of U.S. Patent Covering Lead Drug Candidate ST. LOUIS and BERN, Switzerland, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Immunophotonics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary...

Immunophotonics Announces First Patient Treated in Clinical Study Evaluating IP-001 in Patients with Advanced Solid Tumors ST. LOUIS and BERN, Switzerland, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. announces the first patient treated in the phase 1b/2a clinical trial examining IP-001 in thermally ablated...

Immunophotonics Announces Appointment of Jonathan Knowles to Board of Directors ST. LOUIS, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Immunophotonics, Inc., a biotechnology company focused on the discovery and development of proprietary immune-activating carbohydrate polymers for the...

Immunophotonics Announces Appointment of Jonathan Knowles to Board of Directors BERN, Switzerland, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Immunophotonics, Inc., a biotechnology company focused on the discovery and development of proprietary immune-activating carbohydrate polymers...

Immunophotonics, Inc. Announces First Patient Dosed in a Randomized, Controlled Breast Cancer Clinical Trial for inCVAX – A Novel Investigational Immuno-Oncology Therapy ST. LOUIS, Aug. 23, 2016 (GLOBE NEWSWIRE) -- Immunophotonics today announces that it has dosed its first patient in a randomized & controlled clinical trial to further evaluate the efficacy of...